Of patients improved
with DUPIXENT 200 mg + SOC vs 67% with
placebo + SOC (OR: 1.46 [95% CI: 0.90, 2.35])
DUPIXENT improved asthma control (ACQ-5) and quality of life (AQLQ[S]) in patients with EOS ≥300 cells/µL
Responder rates at Week 52 in Trial 2 (secondary endpoints)1,a-c
ACQ-5 (asthma control)
75%
71%
Of patients improved
with DUPIXENT 300 mg + SOC vs 64% with
placebo + SOC (OR: 1.39 [95% CI: 0.88, 2.19])
with DUPIXENT 300 mg + SOC vs 64% with
placebo + SOC (OR: 1.39 [95% CI: 0.88, 2.19])
AQLQ(S) (quality of life)
71%
Of patients improved
with DUPIXENT 200 mg + SOC vs 55% with
placebo + SOC (OR: 2.02 [95% CI: 1.24, 3.32])
with DUPIXENT 200 mg + SOC vs 55% with
placebo + SOC (OR: 2.02 [95% CI: 1.24, 3.32])
65%
Of patients improved
with DUPIXENT 300 mg + SOC vs 55% with
placebo + SOC (OR: 1.79 [95% CI: 1.13, 2.85])
with DUPIXENT 300 mg + SOC vs 55% with
placebo + SOC (OR: 1.79 [95% CI: 1.13, 2.85])
- a Responder rates were defined as an improvement in score of 0.5 or more (scale ranged from 0 to 6 for ACQ-5 and 1 to 7 for AQLQ[S]).
- b ACQ-5: Asthma Control Questionnaire, 5-item version, a patient-reported measure of asthma control. Higher scores indicate less asthma control; a global score is calculated ranging from 0 to 6. The meaningful clinically important difference is 0.5.
- c AQLQ(S): Asthma Quality of Life Questionnaire, Standardized Version, a patient-reported measure of asthma-related quality of life. Higher scores indicate better quality of life; a global score is calculated ranging from 1 to 7. The meaningful clinically important difference is 0.5.
OR, odds ratio.
